313 related articles for article (PubMed ID: 26091827)
1. Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy.
Behbehani GK; Samusik N; Bjornson ZB; Fantl WJ; Medeiros BC; Nolan GP
Cancer Discov; 2015 Sep; 5(9):988-1003. PubMed ID: 26091827
[TBL] [Abstract][Full Text] [Related]
2. Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones.
Al-Mawali A; Gillis D; Lewis I
J Hematol Oncol; 2016 Jul; 9(1):61. PubMed ID: 27465508
[TBL] [Abstract][Full Text] [Related]
3. Blast cells surviving acute myeloid leukemia induction therapy are in cycle with a signature of FOXM1 activity.
Williams MS; Basma NJ; Amaral FMR; Wiseman DH; Somervaille TCP
BMC Cancer; 2021 Oct; 21(1):1153. PubMed ID: 34711181
[TBL] [Abstract][Full Text] [Related]
4. Immunophenotypic Detection of Measurable Residual (Stem Cell) Disease Using LAIP Approach in Acute Myeloid Leukemia.
Zeijlemaker W; Kelder A; Cloos J; Schuurhuis GJ
Curr Protoc Cytom; 2019 Dec; 91(1):e66. PubMed ID: 31763792
[TBL] [Abstract][Full Text] [Related]
5. MRP1 protein expression in leukemic stem cells as a negative prognostic marker in acute myeloid leukemia patients.
Paprocka M; Bielawska-Pohl A; Rossowska J; Krawczenko A; Duś D; Kiełbiński M; Haus O; Podolak-Dawidziak M; Kuliczkowski K
Eur J Haematol; 2017 Nov; 99(5):415-422. PubMed ID: 28805931
[TBL] [Abstract][Full Text] [Related]
6. Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells.
Han L; Qiu P; Zeng Z; Jorgensen JL; Mak DH; Burks JK; Schober W; McQueen TJ; Cortes J; Tanner SD; Roboz GJ; Kantarjian HM; Kornblau SM; Guzman ML; Andreeff M; Konopleva M
Cytometry A; 2015 Apr; 87(4):346-56. PubMed ID: 25598437
[TBL] [Abstract][Full Text] [Related]
7. Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia.
de Figueiredo-Pontes LL; Pintão MC; Oliveira LC; Dalmazzo LF; Jácomo RH; Garcia AB; Falcão RP; Rego EM
Cytometry B Clin Cytom; 2008 May; 74(3):163-8. PubMed ID: 18200595
[TBL] [Abstract][Full Text] [Related]
8. High proportion of leukemic stem cells at diagnosis is correlated with unfavorable prognosis in childhood acute myeloid leukemia.
Witte KE; Ahlers J; Schäfer I; André M; Kerst G; Scheel-Walter HG; Schwarze CP; Pfeiffer M; Lang P; Handgretinger R; Ebinger M
Pediatr Hematol Oncol; 2011 Mar; 28(2):91-9. PubMed ID: 21214408
[TBL] [Abstract][Full Text] [Related]
9. The rarity of ALDH(+) cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients.
Hoang VT; Buss EC; Wang W; Hoffmann I; Raffel S; Zepeda-Moreno A; Baran N; Wuchter P; Eckstein V; Trumpp A; Jauch A; Ho AD; Lutz C
Int J Cancer; 2015 Aug; 137(3):525-36. PubMed ID: 25545165
[TBL] [Abstract][Full Text] [Related]
10. CD45
Heo SK; Noh EK; Ju LJ; Sung JY; Jeong YK; Cheon J; Koh SJ; Min YJ; Choi Y; Jo JC
BMC Cancer; 2020 Apr; 20(1):285. PubMed ID: 32252668
[TBL] [Abstract][Full Text] [Related]
11. Effect of Compound Zhebei Granule () combined with chemotherapy on surface markers of leukemia stem cell in patients with acute myeloid leukemia.
Wang J; Lai ZL; Chen XY; Li DY; Zhang YY; Ma W; Chu YT; Shi FQ; Yang L; Hou L
Chin J Integr Med; 2016 Jun; 22(6):438-44. PubMed ID: 26666761
[TBL] [Abstract][Full Text] [Related]
12. High GPR56 surface expression correlates with a leukemic stem cell gene signature in CD34-positive AML.
Daga S; Rosenberger A; Quehenberger F; Krisper N; Prietl B; Reinisch A; Zebisch A; Sill H; Wölfler A
Cancer Med; 2019 Apr; 8(4):1771-1778. PubMed ID: 30848055
[TBL] [Abstract][Full Text] [Related]
13. FISH+CD34+CD38- cells detected in newly diagnosed acute myeloid leukemia patients can predict the clinical outcome.
Wang L; Gao L; Xu S; Gong S; Chen L; Lü S; Chen J; Qiu H; Xu X; Ni X; Song X; Zhang W; Yang J; Liu M; Hu X; Wang J
J Hematol Oncol; 2013 Nov; 6(1):85. PubMed ID: 24517186
[TBL] [Abstract][Full Text] [Related]
14. Aldehyde dehydrogenases inhibition eradicates leukemia stem cells while sparing normal progenitors.
Venton G; Pérez-Alea M; Baier C; Fournet G; Quash G; Labiad Y; Martin G; Sanderson F; Poullin P; Suchon P; Farnault L; Nguyen C; Brunet C; Ceylan I; Costello RT
Blood Cancer J; 2016 Sep; 6(9):e469. PubMed ID: 27611922
[TBL] [Abstract][Full Text] [Related]
15. Immunophenotypic features of leukemic stem cells and bulk of blasts in acute myeloid leukemia.
Ivanivska TS; Sklyarenko LM; Zavelevich MP; Philchenkov AA; Koval SV; Polishchuk AS; Gluzman DF
Exp Oncol; 2019 Sep; 41(3):207-209. PubMed ID: 31569935
[TBL] [Abstract][Full Text] [Related]
16. Acquired expression of osteopontin selectively promotes enrichment of leukemia stem cells through AKT/mTOR/PTEN/β-catenin pathways in AML cells.
Mohammadi S; Ghaffari SH; Shaiegan M; Zarif MN; Nikbakht M; Akbari Birgani S; Alimoghadam K; Ghavamzadeh A
Life Sci; 2016 May; 152():190-8. PubMed ID: 27063991
[TBL] [Abstract][Full Text] [Related]
17. Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in
Jiang X; Mak PY; Mu H; Tao W; Mak DH; Kornblau S; Zhang Q; Ruvolo P; Burks JK; Zhang W; McQueen T; Pan R; Zhou H; Konopleva M; Cortes J; Liu Q; Andreeff M; Carter BZ
Clin Cancer Res; 2018 May; 24(10):2417-2429. PubMed ID: 29463558
[No Abstract] [Full Text] [Related]
18. CD33, CD96 and Death Associated Protein Kinase (DAPK) Expression Are Associated with the Survival Rate and/or Response to the Chemotherapy in the Patients with Acute Myeloid Leukemia (AML).
Jiang Y; Xu P; Yao D; Chen X; Dai H
Med Sci Monit; 2017 Apr; 23():1725-1732. PubMed ID: 28391288
[TBL] [Abstract][Full Text] [Related]
19. Increased myeloid precursors in regenerating bone marrow; implications for detection of minimal residual disease in acute myeloid leukemia.
Zeleznikova T; Stevulova L; Kovarikova A; Babusikova O
Neoplasma; 2007; 54(6):471-7. PubMed ID: 17949229
[TBL] [Abstract][Full Text] [Related]
20. Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML.
Blatt K; Herrmann H; Hoermann G; Willmann M; Cerny-Reiterer S; Sadovnik I; Herndlhofer S; Streubel B; Rabitsch W; Sperr WR; Mayerhofer M; Rülicke T; Valent P
Clin Cancer Res; 2014 Jul; 20(13):3589-602. PubMed ID: 24799522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]